Lexicon Pharmaceuticals
LXRX
101 hedge funds and large institutions have $251M invested in Lexicon Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 33 increasing their positions, 39 reducing their positions, and 16 closing their positions.
160% more call options, than puts
Call options by funds: $169K | Put options by funds: $65K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.29% less ownership
Funds ownership: 81.64% → 80.35% (-1.3%)
8% less funds holding
Funds holding: 110 → 101 (-9)
15% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 39
48% less capital invested
Capital invested by funds: $479M → $251M (-$228M)
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$1.16M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.16M |
| 3 |
Walleye Capital
New York
|
+$557K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$551K |
| 5 |
Fisher Asset Management
Camas,
Washington
|
+$547K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$3.14M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.05M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$1.02M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$867K |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$788K |
LXRX Hedge Fund Activity: Q1 2022 in Review
101 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q1 2022, worth a combined $251M — down 48% from $479M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of LXRX and 7 opened new positions — a net loss of 9 holders — while 39 trimmed existing stakes and 33 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $1.16M. The largest seller was Eversept Partners, exiting entirely with an estimated $3.14M sold.
- 101 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q1 2022, down from 110 in Q4 2021.
- Funds reported $251M of Lexicon Pharmaceuticals stock for Q1 2022, down 48% quarter-over-quarter.
- 7 funds opened new Lexicon Pharmaceuticals positions in Q1 2022 and 16 closed out, a net change of -9 holders.
- The largest Lexicon Pharmaceuticals buyer in Q1 2022 was D.E. Shaw & Co, an estimated $1.16M added.
- The largest Lexicon Pharmaceuticals seller in Q1 2022 was Eversept Partners, an estimated $3.14M sold.
Based on aggregated 13F filings for Q1 2022.